Axium Healthcare Puerto Rico is Now Dispensing ELAHERE™
ImmunoGen has selected Axium Healthcare as their exclusive Specialty Pharmacy for the Puerto Rico market to dispense ELAHERE™ for the treatment of adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Axium Healthcare is proud to announce it is now dispensing ELAHERE (mirvetuximab soravtansine-gynx) injection, for intravenous use. This is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate that is indicated for:
- FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens who have not responded to or are no longer responding to treatment with platinum-based chemotherapy and have received 1 to 3 prior types of chemotherapy.
Milton Latoni, VP of Sales & Business Development for Axium Healthcare Puerto Rico, recently shared what access to ELAHERE means for oncology patient in PRs. “ELAHERE is a new kind of treatment called an antibody-drug conjugate (ADC) that is different from traditional chemotherapies and designed to treat cancer in a targeted way. As the leading specialty pharmacy on the island, Axium Healthcare continues adding innovative therapies to our portfolio. We are proud to add ELAHERE to our treatment options for patients who have not responded to previous treatments.”
At Axium Healthcare our clinical and care teams have extensive experience with the treatment challenges that can arise when dealing with Oncology. We are passionate about simplifying the enrollment process for our patients by providing comprehensive financial services and personalized patient care support.
Axium Healthcare:
At Axium Healthcare, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As a leading specialty pharmacy, Axium Healthcare offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Dermatology, HIV, Hepatitis C, Oncology, Multiple Sclerosis, Movement Disorders, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, Rare Diseases plus others. Axium Healthcare services patients island-wide and is ACHC (since 2010) and URAC Accredited (since 2016). Axium Healthcare's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.axiumpr.com.
About Immunogen:
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, ImmunoGen aims to disrupt the progression of cancer and offer patients more good days. ImmunoGen calls this their commitment to TARGET A BETTER NOW™. Learn more about who they are, what they do, and how they do it at www.immunogen.com.
ELEHERE™ is a trademark of ImmunoGen, Inc. Any other trademarks referred to in this release are the property of their respective owners.